Accelerate your upstream process development timelines with simplified clone selection.
Powered by the CompoZr® Zinc Finger Nuclease (ZFN) technology, SAFC has created the first ever commercially available cell line platform that allows for faster, simpler selection and scale up of high producing clones for the production of recombinant protein drugs. The CHOZN® Platform consists of the CHOZN® GS-/- CHO cell line, and an optimized set of cGMP- produced, chemically-defined media and feeds that have been designed with the cell line to maximize production of r-proteins. The CHOZN® Platform system has been designed and tested to perform from initial cell line engineering process and stable cell line selection, through large scale growth and production. The CHOZN® Platform was developed to provide an off the shelf production solution to biopharmaceutical developers who don’t currently have a cell line platform.
For more information, view the Platform Technical Bulletin.
Used for the production of biopharmaceuticals, the cGMP produced and tested CHOZN® GS-/- cell line is the first commercially available glutamine synthetase (GS) knockout CHO line proven to shorten bioproduction times in early development, enabling customers to enhance their speed to market and decrease costs. .Along with the cells, media and feed, SAFC provides extensive user protocols covering transfection through scale up to small scale bioreactors, as well as comprehensive cell line safety testing and development history.